RUNX1/ETO-IN-1

RUNX1/ETO-IN-1 is a RUNX1-ETO oncogenic fusion protein inhibitor that specifically targets the NHR2 oligomerization domain. RUNX1/ETO-IN-1 directly interacts with the NHR2 (KD, app = 39 μM) . RUNX1/ETO-IN-1 exhibits anti-leukemic activity by inducing apoptosis and promoting differentiation in RUNX1/ETO-translocated AML cells. RUNX1/ETO-IN-1 remains essentially uncharged at physiological pH, demonstrating superior membrane permeability[1].

Product Specifications

CAS Number

[923865-06-9]

UNSPSC

12352005

Target

Apoptosis; RUNX

Related Pathways

Apoptosis; Stem Cell/Wnt; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Purity

91.18

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

CC1=CSC2=NC(CNC(C(C)C)C3=CC4=C(OCCCO4)C=C3)=CC(N12)=O

Molecular Formula

C21H25N3O3S

Molecular Weight

399.51

References & Citations

[1]Gopalswamy M, et al. Identification of non-charged 7.44 analogs interacting with the NHR2 domain of RUNX1-ETO with improved antiproliferative effect in RUNX-ETO positive cells. Sci Rep. 2025 May 22;15 (1) :17720.